The Collagen–LAIR1 axis as an emerging immune checkpoint in non-small cell lung cancer

Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blockade has transformed the treatment of non-small cell lung cancer (NSCLC), yet stromal immune exclusion and adaptive suppression limit durable responses. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1; CD305) is an inhibitory collagen-binding receptor that links the extracellular matrix to immune signaling. This Mini Review examines the biological basis, cellular context, and therapeutic implications of the collagen–LAIR1 checkpoint in NSCLC. Experimental lung cancer studies show that increased collagen deposition can accompany CD8+ T-cell dysfunction and resistance to PD-1/PD-L1 blockade, while LAIR1 antagonism or ligand competition can restore antitumor activity in selected models. LAIR1 also influences myeloid cells, although its functions are context dependent: suppressive tumor-associated macrophage programs coexist with evidence that LAIR1 supports normal monocyte and lung macrophage homeostasis. Recent NSCLC studies additionally demonstrate collagen-based physical barriers and fibroblast-mediated immune exclusion that should not automatically be attributed to LAIR1 signaling. We critically evaluate anti-LAIR1 antibodies, LAIR2-based decoy molecules, extracellular-matrix interventions, and combinations with conventional checkpoint inhibitors. Finally, we propose spatially resolved, cell-type-specific biomarker strategies to distinguish receptor-dependent inhibition from collagen architecture and to guide prospective clinical validation. The collagen–LAIR1 axis is a biologically compelling, but clinically unvalidated, immunotherapy target in NSCLC.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-17
DOI
https://doi.org/10.3389/fimmu.2026.2033483
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Collagen–LAIR1 axis as an emerging immune checkpoint in non-small cell lung cancer

Xiao Han, Ran Huo, Xuguang Zhang, Qiaoli Dong et al.
Frontiers in Immunology
Cancer Immunotherapy and Biomarkers
article

The Collagen–LAIR1 axis as an emerging immune checkpoint in non-small cell lung cancer

Xiao Han, Ran Huo, Xuguang Zhang, Qiaoli Dong, Kunjie Wang, Guihua Xue
article en

Abstract

Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blockade has transformed the treatment of non-small cell lung cancer (NSCLC), yet stromal immune exclusion and adaptive suppression limit durable responses. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1; CD305) is an inhibitory collagen-binding receptor that links the extracellular matrix to immune signaling. This Mini Review examines the biological basis, cellular context, and therapeutic implications of the collagen–LAIR1 checkpoint in NSCLC. Experimental lung cancer studies show that increased collagen deposition can accompany CD8+ T-cell dysfunction and resistance to PD-1/PD-L1 blockade, while LAIR1 antagonism or ligand competition can restore antitumor activity in selected models. LAIR1 also influences myeloid cells, although its functions are context dependent: suppressive tumor-associated macrophage programs coexist with evidence that LAIR1 supports normal monocyte and lung macrophage homeostasis. Recent NSCLC studies additionally demonstrate collagen-based physical barriers and fibroblast-mediated immune exclusion that should not automatically be attributed to LAIR1 signaling. We critically evaluate anti-LAIR1 antibodies, LAIR2-based decoy molecules, extracellular-matrix interventions, and combinations with conventional checkpoint inhibitors. Finally, we propose spatially resolved, cell-type-specific biomarker strategies to distinguish receptor-dependent inhibition from collagen architecture and to guide prospective clinical validation. The collagen–LAIR1 axis is a biologically compelling, but clinically unvalidated, immunotherapy target in NSCLC.

Frontiers in ImmunologyVol. 17
Affiliated Hospital of Hebei University (CN)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon